Sign in Subscribe
Drug delivery systems

Exosome-Driven Biohybrid Nanorobots May Revolutionize Targeted Therapy and Personalized Medicine

Strategic Insights

— 1 min read

New research from Amity University has made significant breakthroughs in the development of exosome-driven biohybrid nanorobots, which have the potential to transform the field of medicine by providing a cutting-edge approach in nanomedicine. These nanorobots combine the natural targeting and immune tolerance capabilities of exosomes with the functional versatility of engineered nanomaterials. As a result, they can be designed for guided or autonomous navigation, enabling site-specific drug delivery with minimal cytotoxicity.

Key Takeaways:

  • The research has integrated magnetic, photothermal, or drug-loaded components into exosomes, transforming them into innovative nanoscale delivery systems.
  • Exosomes are increasingly recognized for their clinical potential in treating conditions like Crohn's disease, type 1 diabetes, and COVID-19.
  • Biohybrid EV nanorobots offer enhanced biodistribution, stability, and cellular uptake compared to traditional nanoparticles.
  • The research concluded that this next-generation drug delivery platform holds promise for overcoming limitations of conventional systems while advancing targeted therapy and personalized medicine.
  • Key design challenges include ensuring reproducibility, size control, and functional stability.
  • Amity University researchers who contributed to this study include Sumira Malik, Subham Preetam, Smita Lata, Jutishna Bora, Shailendra Thapliyal, Shalini Mehta, Seema Ramniwas, Ravi Deshwal, Sarvesh Rustagi, and Nayan Talukdar.
  • The development of biohybrid nanorobots may have significant implications for personalized medicine, allowing for tailored treatment approaches based on individual patient needs.

Statistics:

  • The research was published in the journal RSC Advances, a leading publication in the field of chemistry.
  • The study, titled "Exosome-driven biohybrid nanorobots: Bridging Nature and Nanotechnology in Biomedical Innovation," was conducted by researchers from Amity University Jharkhand, India.
  • The research was funded by the Royal Society of Chemistry, which is a global leader in advancing chemical sciences for the benefit of society.
  • The study made significant breakthroughs in the development of biohybrid nanorobots, which have the potential to revolutionize targeted therapy and personalized medicine.

Sources:

  • RSC Advances. (2025;15(40):33390-33409). Exosome-driven biohybrid nanorobots: Bridging Nature and Nanotechnology in Biomedical Innovation.
  • Royal Society of Chemistry. (n.d.). Royal Society of Chemistry. Retrieved from
  • NewsRx. (2025, October 26). Reports from Amity University Provide New Insights into Biohybrids (Exosome-driven Biohybrid Nanorobots: Bridging Nature and Nanotechnology In Biomedical Innovation). Medical Letter on the CDC & FDA, p 648.

Read more